Patents by Inventor Scott Edward Boyken

Scott Edward Boyken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12054531
    Abstract: The present disclosure relates to EGFR-derived polypeptides containing short juxtamembrane sequences, nucleic acids encoding them, and methods of using them to improve cell surface expression of truncated EGFR markers.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: August 6, 2024
    Assignee: LYELL IMMUNOPHARMA, INC.
    Inventors: Howell Franklin Moffett, Marc Joseph Lajoie, Scott Edward Boyken
  • Publication number: 20210380658
    Abstract: The present disclosure related to chimeric antigen receptors (CARs) comprising immunoglobulin (Ig) derived spacers, e.g., hinge or loop regions, fragments thereof, or combinations thereof. Ig derived spacer confers improved properties to the CARs, e.g., increased cytokine release with respect the CARs with spacers not derived from hinge regions and fragments thereof, loop regions from constant domains and fragments thereof, and combinations thereof. Also provided are cells expressing CARs comprising Ig derived spacers regions and methods to use the CARs to treat diseases or disorders, e.g., cancer. Some of the disclosed Ig derived spacers are fragments from, e.g., IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM. In some aspects, the disclosed Ig derived spacers are derived from non-human immunoglobulins, e.g., mouse immunoglobulins such IgG2A. Other Ig derived spacer disclosed are modular constructs comprising several concatenated Ig hinges or fragments thereof.
    Type: Application
    Filed: May 12, 2021
    Publication date: December 9, 2021
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Marc Joseph LAJOIE, Brian Douglas WEITZNER, Scott Edward BOYKEN, Spencer PARK, Yun SONG
  • Publication number: 20210309717
    Abstract: The present disclosure relates to EGFR-derived polypeptides containing short juxtamembrane sequences, nucleic acids encoding them, and methods of using them to improve cell surface expression of truncated EGFR markers.
    Type: Application
    Filed: March 19, 2021
    Publication date: October 7, 2021
    Applicant: Lyell Immunopharma, Inc.
    Inventors: Howell Franklin Moffett, Marc Joseph Lajoie, Scott Edward Boyken